PE20151062A1 - PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO - Google Patents

PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO

Info

Publication number
PE20151062A1
PE20151062A1 PE2015000911A PE2015000911A PE20151062A1 PE 20151062 A1 PE20151062 A1 PE 20151062A1 PE 2015000911 A PE2015000911 A PE 2015000911A PE 2015000911 A PE2015000911 A PE 2015000911A PE 20151062 A1 PE20151062 A1 PE 20151062A1
Authority
PE
Peru
Prior art keywords
quinoline
pyrimid
sense
dionas
diona
Prior art date
Application number
PE2015000911A
Other languages
English (en)
Inventor
Edgar Jacoby
Juergen Reinhardt
Niko Schmiedeberg
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20151062A1 publication Critical patent/PE20151062A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDO-[4,5-b]-QUINOLIN-4,5(3H,10H)-DIONA DE FORMULA (I) DONDE R1, R2, R3, R4 Y R5 SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA. SON COMPUESTOS PREFERIDOS: 2-CICLOBUTIL-10-METIL-3-FENIL-PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONA; 10-ALIL-2-ISOPROPIL-3-FENIL-PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON SUPRESORES DE MUTACIONES SIN SENTIDO SIENDO UTILES EN EL TRATAMIENTO DE HEMOFILIA A Y B, FIBROSIS QUISTICA
PE2015000911A 2012-12-13 2013-12-12 PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO PE20151062A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
PE20151062A1 true PE20151062A1 (es) 2015-08-05

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000911A PE20151062A1 (es) 2012-12-13 2013-12-12 PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO

Country Status (24)

Country Link
US (2) US9649314B2 (es)
EP (1) EP2931282B1 (es)
JP (1) JP6076498B2 (es)
KR (1) KR101760586B1 (es)
CN (2) CN107569487A (es)
AP (1) AP2015008441A0 (es)
AU (1) AU2013358591B2 (es)
BR (1) BR112015013535A2 (es)
CA (1) CA2890692A1 (es)
CL (1) CL2015001610A1 (es)
CR (1) CR20150314A (es)
CU (1) CU20150061A7 (es)
EA (1) EA028673B1 (es)
ES (1) ES2709034T3 (es)
HK (1) HK1209637A1 (es)
IL (1) IL239244A0 (es)
IN (1) IN2015DN03998A (es)
MA (1) MA38157A1 (es)
MX (1) MX363437B (es)
PE (1) PE20151062A1 (es)
PH (1) PH12015501216A1 (es)
SG (1) SG11201503684WA (es)
TN (1) TN2015000262A1 (es)
WO (1) WO2014091446A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107569487A (zh) 2012-12-13 2018-01-12 诺华股份有限公司 作为无义突变抑制子的嘧啶并[4,5‑b]喹啉‑4,5(3H,10H)‑二酮
AP2016009545A0 (en) * 2014-06-03 2016-11-30 Novartis Ag Naphthyridinedione derivatives
ES2743183T3 (es) 2014-06-03 2020-02-18 Novartis Ag Derivados de piridopirimidinodiona como supresores de mutaciones finalizadoras
ES2743184T3 (es) * 2014-06-03 2020-02-18 Novartis Ag Derivados de pirimido[4,5-b]quinolin-4,5(3H,10H)-diona como supresores de mutaciones finalizadoras
CN109152747A (zh) * 2016-04-15 2019-01-04 Uab研究基金会 用于刺激提前终止密码子的通读的方法和化合物
WO2019173437A1 (en) * 2018-03-06 2019-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CA3208313A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) * 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
WO1996028444A1 (en) * 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
ES2770035T3 (es) 2003-04-11 2020-06-30 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
ES2689539T3 (es) 2006-04-03 2018-11-14 Technion Research & Development Foundation Ltd. Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos
JP2010501571A (ja) 2006-08-23 2010-01-21 ニューロジェン・コーポレーション ハロアルキル−置換ピリミジノン誘導体
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
ES2710854T3 (es) 2010-08-05 2019-04-29 Univ Lille Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto
CN107569487A (zh) 2012-12-13 2018-01-12 诺华股份有限公司 作为无义突变抑制子的嘧啶并[4,5‑b]喹啉‑4,5(3H,10H)‑二酮

Also Published As

Publication number Publication date
WO2014091446A1 (en) 2014-06-19
KR101760586B1 (ko) 2017-07-21
MA38157A1 (fr) 2016-12-30
US20170266189A1 (en) 2017-09-21
SG11201503684WA (en) 2015-06-29
IN2015DN03998A (es) 2015-10-02
JP2016503003A (ja) 2016-02-01
IL239244A0 (en) 2015-07-30
AU2013358591B2 (en) 2016-08-25
JP6076498B2 (ja) 2017-02-08
US9649314B2 (en) 2017-05-16
HK1209637A1 (en) 2016-04-08
US20150335646A1 (en) 2015-11-26
PH12015501216A1 (en) 2015-08-17
EA201591105A1 (ru) 2015-10-30
ES2709034T3 (es) 2019-04-12
CU20150061A7 (es) 2015-12-23
CN107569487A (zh) 2018-01-12
AP2015008441A0 (en) 2015-05-31
BR112015013535A2 (pt) 2017-07-11
KR20150092306A (ko) 2015-08-12
CL2015001610A1 (es) 2015-08-07
MX2015007562A (es) 2015-10-14
EA028673B1 (ru) 2017-12-29
AU2013358591A1 (en) 2015-05-28
EP2931282A1 (en) 2015-10-21
EP2931282B1 (en) 2018-10-31
CA2890692A1 (en) 2014-06-19
CN104837490B (zh) 2017-10-03
CN104837490A (zh) 2015-08-12
MX363437B (es) 2019-03-22
TN2015000262A1 (en) 2016-10-03
CR20150314A (es) 2015-08-10

Similar Documents

Publication Publication Date Title
PE20151062A1 (es) PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PH12016501791B1 (en) Muscarinic receptor agonists
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CL2015000829A1 (es) Inhibidores de histona desmetilasas
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
PE20151558A1 (es) Inhibidores tripeptidicos de la epoxicetona proteasa
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
PH12015502118A1 (en) Pyridin-4-yl derivatives
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PE20150709A1 (es) Benzamidas
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
PE20150707A1 (es) Inhibidores de la beta-secretasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed